Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

TRIP-Br1 monoclonal antibody (TB1-27/2)

 
ALX-804-645-C050 50 µg 248.00 USD
 
ALX-804-645-C100 100 µg 378.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:Transcriptional regulator interacting with the PHD-bromodomain 1, SEI-1, SERTA domain-containing protein 1, CDK4-binding protein p34SEI1
 
Clone:TB1-27/2
 
Host:Mouse
 
Isotype:IgG2a
 
Immunogen:Synthetic peptide corresponding to aa 27-42 (D27PGHAAVAQAPPAVAS42) of human TRIP-Br1 [SEI-1].
 
UniProt ID:Q9UHV2
 
Species reactivity:Human, Mouse
Monkey, Porcine
 
Applications:IHC, IP, WB
 
Recommended Dilutions/Conditions:Immunohistochemistry (1:200)
Western Blot (1:1,000-1:5,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
 
Formulation:Liquid. In PBS containing 0.02% sodium azide.
 
Handling:Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
 
Shipping:Shipped on Blue Ice
 
Short Term Storage:+4°C
 
Long Term Storage:-20°C
 
Scientific Background:TRIP-Br1 (SEI-1) functions as physiological integrator of transcriptional regulatory signals at E2F-responsive promoters to ensure proper execution of E2F-dependent cell cycle progression. TRIP-Br1 is defined as an oncogene.
 
804-645-1
Figure 1: Western blot analysis of pig kidney lysates (LLC-PK1) using MAb to TRIP-Br1 (TB1-27/2) (Prod. No. ALX-804-645) at 1:1’000 and 1:5’000.
Please mouse over
804-645-1

Product Literature References

Exploiting the TRIP-Br family of cell cycle regulatory proteins as chemotherapeutic drug targets in human cancer: Z.J. Zang, et al.; Cancer Biol. Ther. 6, 712 (2007), Abstract;

General Literature References

CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation: R. Hayashi, et al.; J. Biol. Chem. 281, 35633 (2006), Abstract; Full Text
Dissection of CDK4-binding and transactivation activities of p34(SEI-1) and comparison between functions of p34(SEI-1) and p16(INK4A): J. Li, et al.; Biochemistry 44, 13246 (2005), Abstract;
SEI family of nuclear factors regulates p53-dependent transcriptional activation: R. Watanabe-Fukunaga, et al.; Genes Cells 10, 851 (2005), Abstract; Full Text
Expression of a human SOCS protein, HSOCP-1, in peripheral blood eosinophils from patients with atopic dermatitis: K. Ogawa, et al.; Int. Arch. Allergy Immunol. 134 Suppl 1, 2 (2004), Abstract;
The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner: J. Li, et al.; Biochemistry 43, 4394 (2004), Abstract;
TRIP-Br links E2F to novel functions in the regulation of cyclin E expression during cell cycle progression and in the maintenance of genomic stability: K.G. Sim, et al.; Cell Cycle 3, 1296 (2004), Abstract;
Regulation of CREB-mediated transcription by association of CDK4 binding protein p34SEI-1 with CBP: T. Hirose, et al.; Int. J. Mol. Med. 11, 705 (2003), Abstract;
The Drosophila gene taranis encodes a novel trithorax group member potentially linked to the cell cycle regulatory apparatus: S. Calgaro, et al.; Genetics 160, 547 (2002), Abstract; Full Text
TRIP-Br: a novel family of PHD zinc finger- and bromodomain-interacting proteins that regulate the transcriptional activity of E2F-1/DP-1: S.I. Hsu, et al.; EMBO J. 20, 2273 (2001), Abstract; Full Text
RBT1, a novel transcriptional co-activator, binds the second subunit of replication protein A: J.M. Cho, et al.; Nucl. Acids Res. 28, 3478 (2000), Abstract; Full Text

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
TRIP-Br1
By biological activity:
TRIP-Br1 Monoclonal antibody
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,